KR102674521B1 - 면역원성 아르기나제 펩타이드 - Google Patents

면역원성 아르기나제 펩타이드 Download PDF

Info

Publication number
KR102674521B1
KR102674521B1 KR1020197012953A KR20197012953A KR102674521B1 KR 102674521 B1 KR102674521 B1 KR 102674521B1 KR 1020197012953 A KR1020197012953 A KR 1020197012953A KR 20197012953 A KR20197012953 A KR 20197012953A KR 102674521 B1 KR102674521 B1 KR 102674521B1
Authority
KR
South Korea
Prior art keywords
seq
arginase
arg
leu
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020197012953A
Other languages
English (en)
Korean (ko)
Other versions
KR20190077381A (ko
Inventor
매즈 홀드 앤더슨
Original Assignee
아이오 바이오테크 에이피에스
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아이오 바이오테크 에이피에스 filed Critical 아이오 바이오테크 에이피에스
Publication of KR20190077381A publication Critical patent/KR20190077381A/ko
Application granted granted Critical
Publication of KR102674521B1 publication Critical patent/KR102674521B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/03—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amidines (3.5.3)
    • C12Y305/03001—Arginase (3.5.3.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020197012953A 2016-10-07 2017-10-06 면역원성 아르기나제 펩타이드 Active KR102674521B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16192794.2 2016-10-07
EP16192794 2016-10-07
PCT/EP2017/075443 WO2018065563A1 (en) 2016-10-07 2017-10-06 Immunogenic arginase peptides

Publications (2)

Publication Number Publication Date
KR20190077381A KR20190077381A (ko) 2019-07-03
KR102674521B1 true KR102674521B1 (ko) 2024-06-11

Family

ID=57123856

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020197012953A Active KR102674521B1 (ko) 2016-10-07 2017-10-06 면역원성 아르기나제 펩타이드

Country Status (19)

Country Link
US (3) US10858642B2 (https=)
EP (2) EP4406613A3 (https=)
JP (1) JP7211938B2 (https=)
KR (1) KR102674521B1 (https=)
CN (1) CN109890399A (https=)
AU (1) AU2017341112B2 (https=)
CA (1) CA3039510A1 (https=)
DK (1) DK3522905T3 (https=)
ES (1) ES2992031T3 (https=)
FI (1) FI3522905T3 (https=)
HR (1) HRP20241486T1 (https=)
HU (1) HUE069077T2 (https=)
IL (1) IL265805B2 (https=)
LT (1) LT3522905T (https=)
MX (1) MX2019003970A (https=)
PL (1) PL3522905T3 (https=)
PT (1) PT3522905T (https=)
SI (1) SI3522905T1 (https=)
WO (1) WO2018065563A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017341112B2 (en) * 2016-10-07 2024-06-27 Io Biotech Aps Immunogenic arginase peptides
GB201815549D0 (en) * 2018-09-24 2018-11-07 Io Biotech Aps Arginase1 polypeptides
GB201818576D0 (en) * 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides
GB201912030D0 (en) * 2019-08-21 2019-10-02 Cancer Research Tech Ltd Binding molecules
US20250327041A1 (en) 2022-02-24 2025-10-23 Io Biotech Aps Nucleotide delivery of cancer therapy
KR20240159833A (ko) 2022-02-24 2024-11-06 아이오 바이오테크 에이피에스 아르기나아제 2 백신

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050313A2 (en) 2004-10-29 2006-05-11 The Board Of Trustees Operating Michigan State University Protection against herbivores
JP2012507301A (ja) 2008-10-31 2012-03-29 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 癌を処置するための操作されたヒトアルギナーゼの組成物および方法
WO2016102272A1 (en) 2014-12-23 2016-06-30 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US5780286A (en) 1996-03-14 1998-07-14 Smithkline Beecham Corporation Arginase II
US20110111424A1 (en) 2001-06-21 2011-05-12 Cell Signaling Technology, Inc. Analysis of ubiquitinated polypeptides
WO2003038444A2 (en) 2001-10-31 2003-05-08 Pfizer Products Inc. Biomarkers of liver function
WO2011008495A2 (en) * 2009-06-29 2011-01-20 The Board Of Regents Of The University Of Texas System Arginase formulations and methods
CN106456723B (zh) 2014-04-29 2021-03-09 康达医药科技有限公司 采用精氨酸酶i调节免疫系统的方法和组合物
AU2017341112B2 (en) * 2016-10-07 2024-06-27 Io Biotech Aps Immunogenic arginase peptides
JP7312106B2 (ja) * 2016-10-27 2023-07-20 アイオー バイオテック エーピーエス 新しいｐｄｌ２化合物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006050313A2 (en) 2004-10-29 2006-05-11 The Board Of Trustees Operating Michigan State University Protection against herbivores
JP2012507301A (ja) 2008-10-31 2012-03-29 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 癌を処置するための操作されたヒトアルギナーゼの組成物および方法
WO2016102272A1 (en) 2014-12-23 2016-06-30 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (hcc) and other cancers

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
NCBI GenBank AEB16014.1(2011.4.12.)*

Also Published As

Publication number Publication date
MX2019003970A (es) 2019-12-05
KR20190077381A (ko) 2019-07-03
IL265805B1 (en) 2024-04-01
PT3522905T (pt) 2024-10-02
AU2017341112A1 (en) 2019-05-02
IL265805A (en) 2019-06-30
DK3522905T3 (da) 2024-10-21
JP2019537562A (ja) 2019-12-26
WO2018065563A1 (en) 2018-04-12
IL265805B2 (en) 2024-08-01
CN109890399A (zh) 2019-06-14
EP3522905A1 (en) 2019-08-14
US10858642B2 (en) 2020-12-08
EP4406613A2 (en) 2024-07-31
SI3522905T1 (sl) 2025-02-28
HUE069077T2 (hu) 2025-02-28
CA3039510A1 (en) 2018-04-12
LT3522905T (lt) 2024-11-11
FI3522905T3 (fi) 2024-10-31
EP3522905B1 (en) 2024-09-25
ES2992031T3 (es) 2024-12-05
EP4406613A3 (en) 2024-10-23
HRP20241486T1 (hr) 2025-01-03
US11981944B2 (en) 2024-05-14
US20190338270A1 (en) 2019-11-07
US20240167013A1 (en) 2024-05-23
PL3522905T3 (pl) 2025-01-07
JP7211938B2 (ja) 2023-01-24
AU2017341112B2 (en) 2024-06-27
US20210139877A1 (en) 2021-05-13

Similar Documents

Publication Publication Date Title
KR102674521B1 (ko) 면역원성 아르기나제 펩타이드
RS53782B1 (sr) Preparati tumor-asociranih peptida i odgovarajuća antikancerska vakcina za tretman glioblastoma (gbm) i drugih kancera
US8323965B2 (en) Identification of antigenic peptides from multiple myeloma cells
KR101585042B1 (ko) 암 백신으로서의 서비빈 펩티드
US20240299450A1 (en) Uses of amphiphiles in immune cell therapy and compositions therefor
JP2023109840A (ja) 新しいｐｄｌ２化合物
CN113966342A (zh) TGF-β疫苗
JP2022507373A (ja) 免疫原性アルギナーゼ２ポリペプチド
WO2019101110A1 (zh) 天花粉蛋白用于致敏和/激活树突状细胞中的应用
JP2022501046A (ja) アルギナーゼ１ポリペプチド
HK40012895B (en) Immunogenic arginase peptides
HK40012895A (en) Immunogenic arginase peptides
Small Interfering DC2007: 5th International meeting on dendritic cell vaccination and other strategies to tip the balance of the immune system, 16–18 July, 2007, Bamberg, Germany
COCHLOVIUS et al. N. 3 Expression of mutated p21 Ras-~ ptides in transfected EBV-Iymphoblasts elicit a strong specific en-response in an autologous
WO2007025705A2 (en) Method for the generation of antigen-specific t-cells and uses thereof

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20190503

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200928

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210913

Patent event code: PE09021S01D

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

Comment text: Final Notice of Reason for Refusal

Patent event date: 20220914

Patent event code: PE09021S02D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230718

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20240404

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20240607

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20240607

End annual number: 3

Start annual number: 1

PG1601 Publication of registration